Search
Search Results
-
Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma
Futibatinib (LYTGOBI ® ) is an oral small molecule compound that selectively, irreversibly and potently inhibits the tyrosine kinase activity of...
-
TGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation
BackgroundIdiopathic pulmonary fibrosis (IPF) bears high mortality due to unclear pathogenesis and limited therapeutic options. Therefore,...
-
Pemigatinib: A Review in Advanced Cholangiocarcinoma
Pemigatinib (Pemazyre ® ), a selective, potent, reversible, oral inhibitor of fibroblast growth factor receptor (FGFR) 1–3, has received conditional...
-
Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma
BackgroundHepatocellular carcinoma (HCC) is the most common liver cancer globally, claiming nearly 1 million lives each year. The overexpression of...
-
Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma
This work provides a summary of guideline recommendations and an expert position on the use of maintenance avelumab therapy based on a review of...
-
FGF/FGFR signaling in health and disease
Growing evidences suggest that the fibroblast growth factor/FGF receptor (FGF/FGFR) signaling has crucial roles in a multitude of processes during...
-
Fibroblast growth factor 8 overexpression is predictive of poor prognosis in pancreatic ductal adenocarcinoma
BackgroundDespite distinctive advances in the field of pancreatic cancer therapy over the past few years, patient survival remains poor. Fibroblast...
-
Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis
IntroductionThe heightened fibroblast growth factor 23 (FGF23) level in patients with chronic kidney disease (CKD) is associated with increased...
-
Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective
Biliary tract cancers (BTCs) are a heterogeneous group of tumors that are rare in Western countries and have a poor prognosis. Three subgroups are...
-
Anlotinib Attenuates Liver Fibrosis by Regulating the Transforming Growth Factor β1/Smad3 Signaling Pathway
BackgroundHepatic stellate cell hyperactivation is a central link in liver fibrosis development, transforming growth factor β 1 (TGF- β 1) is a key...
-
Treating Biliary Tract Cancers: New Targets and Therapies
Biliary tract cancers (BTCs) are rare and aggressive tumors that typically present at an advanced stage when surgical resection is no longer...
-
FGF7 enhances the expression of ACE2 in human islet organoids aggravating SARS-CoV-2 infection
The angiotensin-converting enzyme 2 (ACE2) is a primary cell surface viral binding receptor for SARS-CoV-2, so finding new regulatory molecules to...
-
FGFR2 Controls Growth, Adhesion and Migration of Nontumorigenic Human Mammary Epithelial Cells by Regulation of Integrin β1 Degradation
The role of fibroblast growth factor receptor 2 (FGFR2), an important mediator of stromal paracrine and autocrine signals, in mammary gland...
-
A case of treatment-resistant advanced gastric cancer with FGFR2 gene alteration successfully treated with pemigatinib
Comprehensive genome profiling (CGP) is expected to widen the scope of cancer drug options by identifying the genes involved in carcinogenesis....
-
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
Surufatinib, is a potent inhibitor of vascular endothelial growth factor receptors 1–3; fibroblast growth factor receptor-1; colony-stimulating...
-
Personalisierte Therapie beim metastasierten Urothelkarzinom – Vision oder Wirklichkeit?
BackgroundFor many years personalized treatment of metastatic urothelial cancer (mUC) was not a priority topic in clinical treatment and research....
-
Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma
BackgroundHistone deacetylase (HDAC) class I and IIa are highly expressed in hepatocellular carcinoma (HCC) and associated with decreased survival....
-
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors
BackgroundWe sought to describe corneal epithelial changes after using epidermal (EGFR) or fibroblast growth factor receptor (FGFR) inhibitors as...
-
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors
Immune checkpoint inhibitors are the leading approaches in tumor immunotherapy. The aim of the study was to establish recommended phase 2 doses...
-
Effect of tumor genetics, pathology, and location on fMRI of language reorganization in brain tumor patients
ObjectivesLanguage reorganization may follow tumor invasion of the dominant hemisphere. Tumor location, grade, and genetics influence the...
